Journal Home
Search for

Volume 19, Issue 7, Pages 441-445 (July 2009)


View previous. 5 of 17 View next.

Vitamin D and Cancer Mini-Symposium: The Risk of Additional Vitamin D

Reinhold ViethCorresponding Author Informationemail address

Received 25 April 2007; accepted 16 January 2009. published online 13 April 2009.

Any benefit of vitamin D needs to be balanced against the risk of toxicity, which is characterized by hypercalcemia. Daily brief, suberythemal exposure of a substantial area of the skin to ultraviolet light, climate allowing, provides adults with a safe, physiologic amount of vitamin D, equivalent to an oral intake of about 10,000IU vitamin D3 per day, with the plasma 25-hydroxyvitamin D (25(OH)D) concentration potentially reaching 220 nmol/L (88 ng/mL). The incremental consumption of 40IU/d of vitamin D3 raises plasma 25(OH)D by about 1 nmol/L (0.4 ng/mL). High doses of vitamin D may cause hypercalcemia once the 25(OH)D concentration is well above the top of the physiologic range. The physiological buffer for vitamin D safety is the capacity of plasma vitamin D–binding protein to bind the total of circulating 25(OH)D, vitamin D, and 1,25-dihydroxyvitamin D [1,25(OH)2D]. Hypercalcemia occurs when the free concentration is inappropriately high because vitamin D and its other metabolites have displaced 1,25(OH)2D from vitamin D–binding protein. Evidence from clinical trials shows, with a wide margin of confidence, that a prolonged intake of 10,000IU/d of vitamin D3 poses no risk of adverse effects for adults, even if this is added to a rather high physiologic background level of vitamin D.

Departments of Nutritional Sciences, and Laboratory Medicine and Pathobiology, University of Toronto, and Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada

Corresponding Author InformationAddress correspondence to: Reinhold Vieth, PhD, FCACB, Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, ON, M5G 1X5, Canada. Tel.: (416) 586-5920; fax: (416) 586-8628.

PII: S1047-2797(09)00039-8

doi:10.1016/j.annepidem.2009.01.009


View previous. 5 of 17 View next.